

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713617200>

Transformation of Glucose into a Novel Carbasugar Amino Acid Dipeptide Isostere

Bas Lastdrager^a; Mattie S. M. Timmer^a; Gijsbert A. van der Marel^a; Herman S. Overkleef^a; Mark Overhand^a

^a Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands

To cite this Article Lastdrager, Bas , Timmer, Mattie S. M. , van der Marel, Gijsbert A. , Overkleef, Herman S. and Overhand, Mark(2007) 'Transformation of Glucose into a Novel Carbasugar Amino Acid Dipeptide Isostere', *Journal of Carbohydrate Chemistry*, 26: 1, 41 – 59

To link to this Article: DOI: 10.1080/07328300701252623

URL: <http://dx.doi.org/10.1080/07328300701252623>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Transformation of Glucose into a Novel Carbasugar Amino Acid Dipeptide Isostere

Bas Lastdrager, Mattie S. M. Timmer, Gijsbert A. van der Marel, Herman S. Overkleeff, and Mark Overhand

Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands

The synthesis of a novel carbasugar amino acid (**15**), starting from D-glucose and using the Ferrier rearrangement as a key step, is reported. Compound **15** is implemented as dipeptide isostere in the synthesis of a Leu-enkephalin analog.

Keywords: Sugar amino acid, Peptidomimetic, Carbasugar, Leu-enkephalin, Mukaiyama-Michael addition

INTRODUCTION

Sugar amino acids (SAAs) are defined as carbohydrate-based compounds that feature an amine and a carboxylate.^[1] As such, SAAs are widely spread in nature, and neuraminic acid and *N*-acetyl muramic acid constitute important structural elements in many oligo(poly)saccharides and glycoconjugates. Interestingly, SAAs in nature are almost exclusively linked through interglycosidic bonds, not through amide bonds. The full potential of SAAs^[2] as carbohydrate-peptide hybrids was recognized first by Kessler and coworkers,^[3] who disclosed an efficient synthesis of D-glucose-derived SAAs and their incorporation in a series of linear and cyclic oligopeptide structures. Inspired by this work, many researchers have become actively involved in SAA-related research. SAA homooligomers have been generated with the aim to attain oligosaccharide mimics that have the interglycosidic linkages replaced by amide bonds.^[4] Cyclic SAA homooligomers have been prepared^[5,6] with the ultimate goal to

Received August 12, 2006; Accepted January 30, 2007.

Address correspondence to Mark Overhand, Leiden Institute of Chemistry, Gorlaeus Laboratories, P. O. Box 9502, 2300 RA Leiden, The Netherlands. E-mail: overhand@chem.leidenuniv.nl


develop cyclodextrin analogous receptor molecules.^[7] The relevance of the hybrid nature of SAAs comes to the fore in the multitude of reported applications in which selected amino acid residues are replaced in biologically relevant oligopeptides. Here the aim is twofold: The nature of the parent carbohydrate (the furan or pyran ring) in combination with the positioning of the amine and carboxylate may impart a desired secondary structure on the target oligopeptide, whereas the residual functionalities on the furan/pyran core may be used to introduce additional desirable properties to the peptide.^[8]

In conjunction with the growing interest in the application of SAAs, recent years have witnessed numerous reports describing synthetic strategies toward new SAAs.^[9] Next to aiming for control over the relative positioning of the amine- and carboxylate functionalities (as in α , β , γ , δ , and ϵ SAAs), research objectives in these studies include the development of constrained SAAs, for instance, through annulation of a second ring system,^[10] but also the preparation of linear SAA derivatives.^[11]

Given the extensive research efforts involving SAAs, reported examples of SAA building blocks in which the ring oxygen is replaced by carbon^[12] are scarce. This is surprising, especially when considering the numerous strategies available for transforming a carbohydrate into carbasugars.^[13] We here describe the application of the Ferrier rearrangement^[14] of a carbohydrate-derived enopyranoside and its transformation into carbasugar amino acid **15** (CSAA). The applicability of dipeptide isostere CSAA **15** in standard solid phase peptide synthesis is demonstrated by the synthesis of Leu-enkephalin derivative **21**.

RESULTS AND DISCUSSION

Our synthetic approach commenced with the five-step conversion of commercially available methyl α -D-glucopyranoside **1** into the enopyranoside **2** in 61% yield following a literature procedure (Sch. 1).^[15] Submitting compound **2** to Ferrier rearrangement conditions (mercury(II)chloride in aqueous media at elevated temperature) cleanly provided the known functionalized cyclohexanone **3** in 80% yield. Ketone **3** was converted into the intermediate enone **4**. At this stage, it was envisioned that the required carboxymethyl substituent could be introduced via a Michael addition. In a first attempt, treatment of compound **4** with the diethylmalonate anion, generated under the agency of sodium hydride or sodium methoxide, did not result in the expected 1,4-addition. Instead, elimination of benzyl alcohol followed by tautomerization led to the quantitative formation of phenol derivative **5**. Because of the apparent instability of enone **4** toward basic conditions, attention was focused on the Lewis acid-mediated Mukaiyama-Michael addition. Treatment of compound **4** with 1-(*tert*-butyldimethylsilyloxy)-1-ethoxyethene^[16] and titanium(IV)chloride led to 1,2-addition giving allylic alcohol **6** as a single diastereoisomer in 78%




Scheme 1: Conditions: i) reference 15 ii) HgCl_2 (1.1 equiv.), acetone/ H_2O (2:1), reflux, 2 h, 80%. iii) MsCl (2.7 equiv.), DMAP (cat.), pyr., rt, 2 h, 87%. iv) diethylmalonate (1.5 equiv.), NaH or NaOEt (1.5 equiv.), THF, rt, 45 min, 99%. v) $\text{TBSOC}(\text{OEt})=\text{CH}_2$ (1.5 equiv.), TiCl_4 (1.5 equiv.), DCM, -78°C , 30 min, 78%. vi) $\text{TBSOC}(\text{OEt})=\text{CH}_2$ (1.5 equiv.), SnCl_4 (1.5 equiv.), DCM, -78°C , 20 min, 55%. vii) $\text{TBSOC}(\text{OEt})=\text{CH}_2$ (1.5 equiv.), LiClO_4 (5.0 equiv.), Et_2O , rt, 48 h, 73%. viii) $\text{TBSOC}(\text{OMe})=\text{CH}_2$ (3.0 equiv.), LiClO_4 (10.0 equiv.), Et_2O , rt, 30 min, 98%. ix) HF-pyr., THF/pyr. (4:1), rt, 30 min, 99%. x) *p*-MeOBnNH₂ (2.0 equiv.), $\text{Na}(\text{OAc})_3\text{BH}$ (1.5 equiv.), HOAc (1.0 equiv.), 1,2-DCE, rt, 1 h, **11**: 51%, **12**: 15% (2 steps). xi) CAN (2.5 equiv.), $\text{H}_2\text{O}/\text{MeCN}$ (1:2), rt, 24 h, 56%. xii) LiOH, $\text{H}_2\text{O}/\text{dioxane}$ (1:4), rt, 3 h, quant. xiii) FmocOSu, sat. aq. $\text{NaHCO}_3/\text{dioxane}$ (4:1), 17 h, 92%.

yield. Despite the good yield and selectivity, this approach was rendered ineffective as the tertiary allylic hydroxyl functionality proved to be inert toward further transformations. Upon application of tin(IV)chloride as Lewis acid in dichloromethane, 1,4-addition was achieved resulting in the formation of

ester **7** in 55% as an inseparable mixture of isomers. The yield of this reaction could be further optimized by switching to lithium perchlorate in Et₂O,^[17] affording after 48 h reaction time ester **7** in 73% yield, again as a mixture of diastereoisomers (4:1). By changing the alkylating species to (*tert*-butyldimethylsilyloxy)-1-methoxyethene and using a larger excess of reagents, a spectacular change in the outcome of the reaction was observed. Using this reagent, enone **4** was consumed in only 30 min, resulting in Michael adduct **8** as a single diastereoisomer in 98% yield. The newly created stereocenter was unambiguously assigned using NMR spectroscopy.

In continuation of our synthetic studies, silyl enol ether **8** was transformed into ketone **9** amenable for ensuing reductive amination. Initially, the conversion of compound **9** from **8** was hampered by the formation of the elimination product **10** in yields varying from 70% to 80%, under several desilylating conditions. Fortunately, it was found that elimination could be suppressed completely by switching to HF·pyridine as the desilylating agent. Under these conditions, ketone **9** was isolated as the sole product and in quantitative yield. Importantly, the reaction with HF·pyridine was complete within 30 min. Prolonged reaction times led to the formation of enone **10** through elimination of benzyl alcohol. It was found that this transformation also occurs, over time, upon storage of **9**, dictating the necessity to proceed with the next step directly. Thus, after hydrolysis and workup, immediate reductive amination employing 4-methoxybenzylamine, acetic acid, and sodium triacetoxyborohydride afforded CSAA **11** in 51% over two steps. Rather surprisingly, complete epimerization at C1 occurred under the conditions applied. The absolute configuration of **11** was firmly established by NOE difference experiments, with key NOEs between H5b-H1 and H5a-H3. In addition, the *trans*-disposition of the newly introduced amine- and carboxymethyl substituent was assigned. The epimerization of the stereocenter at C1 is most likely the result of tautomerization of the intermediate imine, resulting in the formation of amine **11** as the more stable isomer. In a competing process, benzyl alcohol proved to be prone to elimination, leading to the formation of enol ether **12** as major side product, in a yield of 15% over the last two steps. Removal of the *N*-methoxybenzyl group of **11**, using ceric ammonium nitrate (CAN), liberated the free amine to give compound **13**. Saponification of the methyl ester under the agency of LiOH furnished amino acid **14** in 56% yield over two steps. Protection of the amine function of **14** was accomplished using Fmoc-OSu in saturated aqueous NaHCO₃/dioxane, to give CSAA **15** in a yield of 92%.

CSAA **15** was applied in a standard Fmoc-based solid phase peptide synthesis protocol toward the synthesis of a novel Leu-enkephalin derivative (Sch. 2). Thus, Wang resin **16** was transformed in a standard way to give H-Phe-Leu-Wang resin **17**. Condensation of acid **15** with **17** using HCTU as coupling agent proceeded smoothly to give immobilized tripeptide **18**. After removal of the Fmoc group, further elongation with a Boc-protected tyrosine



Scheme 2: Conditions: i) a) DIC, DMAP, Fmoc-Leu-OH, CH₂Cl₂; b) 20% piperidine in DMF, 3 × 10 min; c) Fmoc-Phe-OH, HCTU, DIPEA, DMF, 3 × 1 h; d) 20% piperidine in DMF, 3 × 10 min. ii) **15** (2.0 equiv.), HATU (0.95 equiv.), DIPEA, DMF (2.5 equiv.), 2 × 10 min. iii) a) 20% piperidine in DMF, 3 × 10 min; b) Boc-Tyr(*t*-Bu)-OH, HCTU, DIPEA, DMF, 2 h. iv) TFA/TIS/H₂O (95:2.5:2.5), 15 min; 95% v) H₂, 10% Pd/C (cat.), HOAc (1.0 equiv.), *t*-BuOH/H₂O (1:1), 17 h, rt, quant.

(19) and subsequent acidic cleavage from the resin, along with removal of the acid labile protective groups, gave partially deprotected peptide **20**. Finally, hydrogenolysis of the benzyl ethers followed by reverse-phase HPLC purification afforded Leu-enkephalin analog **21** in 95% overall yield.

In summary, a synthetic route to novel CSAA **15** was developed having a high-yielding and stereoselective lithium perchlorate assisted Mukaiyama-Michael 1,4-addition on enone **4** as a key step. In addition, dipeptide isostere **15** was successfully applied in a solid phase protocol toward Leu-enkephalin analog **21**.

EXPERIMENTAL SECTION

General Methods and Materials

Acetone, 1,2-dichloroethane (1,2 DCE), dichloromethane (DCM), dimethyl formamide (DMF), 1,4-dioxane, ethanol, *n*-hexane, pyridine (pyr.), and toluene (Biosolve) were stored over molecular sieves (4Å). Acetonitrile and methanol (HPLC grade) (Biosolve) were stored over molecular sieves (3Å). Diethyl ether and tetrahydrofuran (THF) (Biosolve) were distilled from LiAlH₄ prior to use. Eluents ethyl acetate, petroleum ether (40–60), and toluene (Riedel-de Haën) were of technical grade and distilled prior to use. All other chemicals were used as received. Abbreviations of chemicals used in solid phase peptide

synthesis: Boc: *tert*-butyloxycarbonyl; DIC: diisopropylcarbodiimide; DiPEA: *N,N*-diisopropylethylamine; DMAP: 4-(dimethylamino)pyridine; Fmoc: 9-fluorenylmethyloxycarbonyl; Glu: L-glutamic acid; Gly: glycine; HATU: 2-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HCTU: 2-(6-chloro-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; Leu: L-leucine; Phe: L-phenylalanine; Su: succinimide; TFA: trifluoroacetic acid; TIS: triisopropylsilane; Tyr: L-tyrosine. All reactions were performed under an inert atmosphere and at ambient temperature unless stated otherwise. Prior to reactions that require anhydrous conditions, traces of water from starting material and reagents were removed by coevaporation with toluene or 1,2-dichloroethane. All solvents were removed by evaporation under reduced pressure. Reactions were monitored by TLC analysis using DC-fertigfolien (Schleicher & Schuell, F1500, LS254) or HPTLC aluminum sheets (Merck, silica gel 60, F254). Compounds were visualized by UV absorption (254 nm) where applicable and by spraying with 20% H₂SO₄ in ethanol followed by charring at ~150°C or by spraying with a solution of (NH₄)₆Mo₇O₂₄ · 4H₂O (25 g/L) and (NH₄)₄Ce(SO₄)₄ · 2H₂O (10 g/L) in 10% sulfuric acid followed by charring at ~150°C. Olefins were visualized by spraying with a solution of KMnO₄ (2%) and K₂CO₃ (1%) in water. Column chromatography was performed on silica gel (Merck, 40–60 μm). Optical rotations ($[\alpha]_D^{20}$) were measured on a Propol automatic polarimeter (sodium D line, λ = 589 nm). ¹H and ¹³C APT NMR spectra were recorded on a Jeol JNM-FX-200 (200/50.1 MHz), a Bruker 300 WM-300 (330/75 MHz), a Bruker AV 400 (400/100 MHz), or a Bruker DMX-600 (600/150 MHz) spectrometer. Chemical shifts (δ) are given in ppm relative to tetramethylsilane as internal standard. Coupling constants (*J*) are given Hz. Where indicated, NMR-peak assignments were made using COSY and NOESY experiments. Infrared spectra were recorded on a Shimadzu FTIR-8300 and data are reported in cm⁻¹. Mass spectra were recorded on a PE/Sciex API 165 instrument with an ion spray interface. High-resolution mass spectra and MS/MS were recorded on a Finnigan LTQ-FT (Thermo electron). LC-MS analysis was conducted on a Jasco system (detection simultaneously at 214 nm and 254 nm) equipped with an Alltima C-18 analytical column (Alltech, 4.6 mm × 150 mm, 5-μm particle size). Preparative HPLC was performed on a BioCad Vision (Applied Biosystems, Inc.) using a Alltima C-18 column (Alltech, 10.0 mm × 250 mm, 5 μm particle size).

(2*S*,3*R*,4*S*,5*R*/*S*)-2,3,4-Tris-benzyloxy-5-hydroxycyclohexanone (3)

Compound **2** (5.96 g, 13.36 mmol) was dissolved in a mixture of acetone/water (2:1). HgCl₂ (3.99 g, 14.69 mmol, 1.1 equiv.) was added and the mixture was heated under reflux. After 2 h the mixture was cooled to rt and

concentrated. The resulting white solid was dissolved in DCM, washed with water (2×) and brine (2×). The organic layer was separated, dried (MgSO₄), filtered, and concentrated. Purification by silica gel column chromatography (EtOAc/PE 1:3 to 2:3) gave **3** as a mixture of hydroxyketones in a combined overall yield (4.64 g, 10.73 mmol) of 80%. Major isomer **3S**: ¹³C NMR (50 MHz, CDCl₃): δ 204.0 (C-1), 138.3, 137.6 (3 × C_q Bn), 128.6, 128.4, 128.2, 127.9, 127.8, 127.6, 127.5, 127.1 (CH_{arom}), 85.2, 81.6, 81.4 (C-2, C-3, C-4), 75.7, 73.3, 72.9 (3 × CH₂ Bn), 66.3 (C-5), 42.6 (C-6). Minor isomer **3R**: ¹³C NMR (50 MHz, CDCl₃): δ 203.2 (C-1), 138.0, 137.9, 137.4 (3 × C_q Bn), 128.6, 128.4, 128.1, 128.0, 127.9 (CH_{arom}), 85.9, 84.6, 81.9 (C-2, C-3, C-4), 75.6, 75.3, 73.5 (3 × CH₂ Bn), 67.9 (C-5), 44.1 (C-6).

(4*S*,5*R*,6*S*)-4,5,6-Tris-benzyloxycyclohex-2-enone (**4**)

To a mixture of alcohol **3** (0.432 g, 1.00 mmol) and mesylchloride (0.209 mL, 2.7 mmol, 2.7 equiv.) dissolved in pyridine (10 mL) was added a catalytic amount of DMAP. After 2 h the reaction was complete according to TLC analysis (EtOAc/PE 1:1). Ice was added and the mixture was extracted with Et₂O. The organic layer was separated, washed with brine, dried (MgSO₄), and concentrated. After purification by column chromatography (EtOAc/PE 1:3 to 1:1), unsaturated ketone **4** was obtained (0.361 g, 0.87 mmol) in a yield of 87%. ¹H NMR (200 MHz, CDCl₃): δ 7.46–7.26 (m, 15H, CH_{arom}), 6.81 (dd, 1H, *J*_{3,2} = 10.2 Hz, *J*_{3,4} = 2.2 Hz, H-3), 6.39 (dd, 1H, *J*_{2,3} = 10.2 Hz, *J*_{2,4} = 2.2 Hz, H-2), 5.11–4.70 (m, 6H, 3 × CH₂ Bn), 4.35 (dt, 1H, *J*_{4,2} = *J*_{4,3} = 2.2 Hz, *J*_{4,5} = 7.3 Hz, H-4), 4.04 (d, 1H, *J*_{6,5} = 10.2 Hz, H-6), 3.97 (dd, 1H, *J*_{5,4} = 7.3 Hz, *J*_{5,6} = 10.2 Hz, H-5). ¹³C NMR (50 MHz, CDCl₃): δ 197.3 (C-1), 148.0 (C-3), 138.1, 137.7, 137.5 (3 × C_q Bn), 128.5 (C-2), 128.3–127.7 (CH_{arom}), 84.6, 83.7, 78.9 (C-4, C-5, C-6), 75.6, 74.4, 73.5 (3 × CH₂).

2,4-Bis(benzyloxy)phenol (**5**)

To a mixture of NaH (6 mg, 0.15 mmol 60% dispersion in mineral oil, 1.5 equiv.) or NaOEt (0.15 mL 1.0 M, prepared from 103 mg Na in 45.0 mL EtOH, 1.5 equiv.) in freshly distilled THF (2.5 mL) was added diethylmalonate (23 μL, 0.15 mmol, 1.5 equiv.) at 0°C. After 15 min of stirring a solution of unsaturated ketone **4** (42 mg, 0.10 mmol) in THF (0.5 mL) was added dropwise and the mixture was allowed to reach rt. After 45 min TLC analysis (EtOAc/PE 1:4) revealed complete consumption of enone **4** and the reaction was quenched by addition of water and diluted with EtOAc. The aqueous layer was separated and extracted once more with EtOAc. The combined organic layers were washed with water and brine, dried (MgSO₄), and concentrated. Purification of the residue by column chromatography (PE to EtOAc/PE 1:19) gave phenol derivative **5** (30 mg, 0.10 mmol) in a quantitative yield. ¹H NMR (200 MHz, CDCl₃): δ 7.42–7.31 (m, 10H, CH_{arom} Bn), 6.84 (d, 1H, *J*_{6,5} = 8.8 Hz, H-6),

6.63 (d, 1H, $J_{3,5} = 2.9$ Hz, H-3), 6.48 (dd, 1H, $J_{5,3} = 2.9$ Hz, $J_{5,6} = 8.8$ Hz, H-5), 5.28 (s, 1H, OH), 5.04 (s, 2H, CH₂ Bn), 4.97 (s, 2H, CH₂ Bn). ¹³C NMR (50 MHz, CDCl₃): δ 146.2, 140.2, 140.2, 137.1, 136.1 (5 × C_q), 128.6, 128.5, 128.3, 127.8, 127.5, 126.9 (CH Bn), 114.3, 106.1, 101.7 (C-3, C-5, C-6), 71.0, 70.7 (2 × CH₂ Bn). MS (ESI): $m/z = 307.1$ [M + H]⁺, 329.2 [M + Na]⁺, 635.4 [2M + Na]⁺.

(4S,5R,6S)-4,5,6-Tris(benzyloxy)-1-ethoxycarbonylmethylcyclohex-2-enol (6)

α,β -Unsaturated ketone **4** (0.124 g, 0.30 mmol) was dissolved in freshly distilled DCM (2.5 mL) under an argon atmosphere. 1-(*tert*-Butyldimethylsilyloxy)-1-ethoxyethene^[16] (91.0 mg, 0.45 mmol, 1.5 equiv.) was added and the mixture was cooled to -78°C . After dropwise addition of TiCl₄ (49.6 μL , 0.45 mmol, 1.5 equiv.), the mixture turned dark red. After 30 min TLC analysis (EtOAc/PE 1:3) showed complete disappearance of starting material along with the formation of a lower running spot. The reaction was quenched by addition of water (1.0 mL) and warmed to rt, after which the red color disappeared. The mixture was diluted with Et₂O and the separated organic layer was collected, washed with brine, dried (MgSO₄), and concentrated. Purification of the residue by silica gel column chromatography (EtOAc/PE 1:19 to 1:9) gave 1,2-adduct **6** (0.117 g, 0.23 mmol, 78%). ¹H NMR (400 MHz, CDCl₃): δ 7.35–7.24 (m, 15H, CH_{arom}), 5.80 (2 × dd, 2H, $J = 1.8$ Hz, $J = 10.2$ Hz, H-2, H-3), 5.09 (d, 1H, $J = 11.2$ Hz, CH Bn), 4.91 (d, 1H, $J = 11.0$ Hz, CH Bn), 4.85 (d, 1H, $J = 11.0$ Hz, CH Bn), 4.69 (s, 2H, CH₂ Bn), 4.69 (d, 1H, $J = 11.2$ Hz, CH Bn), 4.16 (dt, 1H, $J = 1.8$ Hz, $J_{4,5} = 7.8$ Hz, H-4), 4.09 (dd, 1H, $J_{5,4} = 7.8$ Hz, $J_{5,6} = 9.8$ Hz, H-5), 4.01 (q, 2H, $J = 7.1$ Hz, CH₂ Et), 3.66 (d, 1H, $J_{6,5} = 9.8$ Hz, H-6), 3.36 (s, 1H, OH), 2.57 (dd, 2H, $J = 14.3$ Hz, CH₂CO), 1.18 (t, 3H, $J = 7.1$ Hz, CH₃ Et). ¹³C NMR (100 MHz, CDCl₃): δ 170.5 (C=O), 138.6, 138.4, 138.1 (3 × C_q Bn), 129.8, 129.7 (C-2, C-3), 128.3–127.5 (CH_{arom}), 81.3 (C-5), 80.4 (C-6), 80.1 (C-4), 75.5, 75.2 (2 × CH₂ Bn), 72.2 (C-1), 71.8 (CH₂ Bn), 60.6 (CH₂ Et), 43.4 (CH₂CO), 14.1 (CH₃ Et). IR (thin film): 3030, 1728, 1497, 1454, 1367, 1302, 1209, 1177, 1067, 1026, 734, 696 cm⁻¹. MS (ESI): $m/z = 503.4$ [M + H]⁺, 520.3 [M + NH₄]⁺, 1005.7 [2M + H]⁺, 1022.7 [2M + NH₄]⁺.

(3R/S,4S,5R,6S)-4,5,6-Tris-benzyloxy-1-(*tert*-butyldimethylsilyloxy)-3-ethoxycarbonylmethylcyclohexene (7)

SnCl₄ mediated Mukaiyama-Michael addition: To a solution of unsaturated ketone **4** (57 mg, 0.14 mmol) in freshly distilled DCM (1.0 mL) was added a solution of silylketen acetal (50 mg, 0.25 mmol, 1.8 equiv.) in DCM (1.0 mL) under an argon atmosphere. The mixture was cooled to -78°C and two drops of SnCl₄ were added. After 20 min TLC analysis (EtOAc/PE 1:4) revealed complete consumption of starting material, water (0.5 mL) was

added, and the mixture was warmed to rt. The mixture was diluted with Et₂O and the organic layer was separated. After extraction of the aqueous layer with Et₂O, all organic layers were combined, dried (MgSO₄), and concentrated. Purification of the residue by column chromatography (EtOAc/PE 1:19) gave ester **7** as a colorless oil as a mixture of diastereoisomers (47 mg, 0.076 mmol, 55%).

LiClO₄ mediated Mukaiyama-Michael addition: To a solution of unsaturated ketone **4** (83 mg, 0.20 mmol) in freshly distilled Et₂O (2.0 mL) was added a solution of silylketene acetal (61 mg, 0.30 mmol, 1.5 equiv.) in Et₂O (0.3 mL) at rt. Next, a 1.0 M solution of LiClO₄ in Et₂O (1.0 mL, 0.106 g, 5.0 equiv.) was added. After 48 h, TLC analysis (EtOAc/PE 1:4) showed all starting material was converted into a higher running spot. The reaction was quenched by addition of sat. aq. NaHCO₃ and the organic layer was separated, washed with brine, dried (MgSO₄), and concentrated. Purification of the residue as described above resulted in 1,4-addition product **7** (90 mg, 0.15 mmol, 73%) as an inseparable mixture of diastereoisomers. ¹H NMR did not provide useful data. ¹³C NMR (200 MHz, CDCl₃): δ 173.0, 172.2 (C=O), 149.6, 149.2 (C-1), 128.2, 127.9, 127.8, 127.6, 127.4 (CH_{arom}), 106.3, 106.1 (C-2), 84.7, 82.0, 81.2, 81.0, 80.0, 78.2 (C-4, C-5, C-6), 75.0, 74.8, 74.6, 74.0, 73.7, 72.1 (CH₂ Bn), 60.3 (CH₂ Et), 37.4, 36.1 (CH₂C=O), 37.0, 33.0 (C-1), 25.8 (C-3), 18.2, 16.2 (C_q TBS), 14.2 (CH₃ Et). MS (ESI): *m/z* = 617.5 [M + H]⁺, 639.4 [M + Na]⁺.

(3*S*,4*S*,5*R*,6*S*)-4,5,6-Tris-benzyloxy-1-(*tert*-butyldimethylsilyloxy)-3-methoxycarbonylmethylcyclohexene (8)

To a 1.0 M solution of LiClO₄ in Et₂O (110 mL) was added compound **4** (4.575 g, 11.04 mmol) at rt. This mixture was stirred until the ketone dissolved completely, followed by the addition of (*tert*-butyldimethylsilyloxy)-1-methoxyethene (7.23 mL, 33.11 mmol, 3.0 equiv.). Stirring was continued for 30 min after which TLC analysis (EtOAc/toluene 1:19) indicated complete disappearance of starting material together with the formation of a higher running spot. After quenching the reaction, by addition of sat. aq. NaHCO₃, the organic layer was separated and the aqueous layer was extracted once more with Et₂O. All ether layers were combined, dried (MgSO₄), filtered, and concentrated. Purification of the residue by silica gel column chromatography (EtOAc/toluene 1:49) gave methylester **8** (6.53 g, 10.83 mmol, 98%) as a single stereoisomer. [α]_D²⁰ -18.9 (*c* 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.42–7.21 (m, 15H, CH_{arom}), 4.94 (d, 1H, *J*_{2,3} = 5.8 Hz, H-2), 4.85 (d, 1H, *J* = 11.0 Hz, CH Bn), 4.82 (d, 1H, *J* = 11.0 Hz, CH Bn), 4.71 (d, 1H, *J* = 11.0 Hz, CH Bn), 4.70 (d, 1H, *J* = 11.0 Hz, CH Bn), 4.63 (s, 2H, CH₂ Bn), 4.00 (d, 1H, *J*_{6,5} = 6.2 Hz, H-6), 3.83 (dd, 1H, *J*_{5,4} = 9.8 Hz, *J*_{5,6} = 6.2 Hz, H-5), 3.72 (dd, 1H, *J*_{4,3} = 5.6 Hz, *J*_{4,5} = 9.8 Hz, H-4), 3.59 (s, 3H, CH₃ OMe), 3.10 (ddt, 1H, *J*_{3,CHH} = *J*_{3,4} = 5.6 Hz, *J*_{3,CHH} = 8.9 Hz, *J*_{3,2} = 5.8 Hz, H-3), 2.79 (dd, 1H,

$J_{CHH,CHH} = 15.8$ Hz, $J_{CHH,3} = 5.6$ Hz, *CHH*), 2.26 (dd, 1H, $J_{CHH,CHH} = 15.8$ Hz, $J_{CHH,3} = 8.9$ Hz, *CHH*), 0.92 (s, 9H, $3 \times$ CH₃ *t*-Bu), 0.16 (s, 3H, CH₃ TBS), 0.15 (s, 3H, CH₃ TBS). ¹³C NMR (100 MHz, CDCl₃): δ 172.6 (C=O), 149.3 (C-1), 138.4, 138.1 ($3 \times$ C_q Bn), 128.6, 128.2, 128.1, 127.8, 127.7, 127.4, 127.3, 127.2, 127.0 (CH_{arom}), 106.0 (C-2), 80.6 (C-6), 79.4 (C-5), 77.8 (C-4), 74.0, 73.5, 71.1 ($3 \times$ CH₂ Bn), 50.8 (CH₃ OMe), 35.5 (CH₂CO), 32.7 (C-3), 25.4 (CH₃ *t*-BuSi), 17.8 (C_q *t*-BuSi), -4.7, -4.9 ($2 \times$ CH₃ SiMe). IR (thin film): 3032, 2928, 2858, 2359, 1734, 1661, 1454, 1205, 1094, 839, 696 cm⁻¹. MS (ESI): $m/z = 603.4$ [M + H]⁺, 625.4 [M + Na]⁺. HRMS (ESI): calcd for [C₃₆H₄₆O₆Si + NH₄]⁺ 620.3407. Found 620.3439.

(2*S*,3*R*,4*S*,5*R*)-2,3,4-Tris-benzyloxy-5-methoxycarbonylmethylcyclohexanone (**9**)

To a solution of enol ether **8** (0.301 g, 0.50 mmol) dissolved in THF (2.0 mL) and pyridine (0.5 mL) was added HF-pyridine (70/30 v/v, 0.25 mL). After 30 min water and Et₂O were added to the reaction mixture. The organic phase was separated and the aqueous phase was extracted once more with Et₂O. All organic layers were combined, dried (MgSO₄), filtered, and concentrated. Purification of the residue by column chromatography (EtOAc/PE 1:9 to 1:4) gave ketone **9** (0.242 g, 0.495 mmol) in a yield of 99%. $[\alpha]_D^{20} -60.6$ (*c* 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.39–7.7.22 (m, 15H, CH_{arom}), 4.86 (d, 1H, $J = 11.8$ Hz, CH Bn), 4.75 (d, 1H, $J = 11.1$ Hz, CH Bn), 4.71 (d, 1H, $J = 11.1$ Hz, CH Bn), 4.60 (d, 1H, $J = 11.4$ Hz, CH Bn), 4.50 (d, 1H, $J = 11.8$ Hz, CH Bn), 4.49 (d, 1H, $J = 11.4$ Hz, CH Bn), 4.09 (d, 1H, $J = 6.9$ Hz, H-2), 3.80–3.75 (m, 2H, H-3, H-4), 3.59 (s, 3H, CH₃ OMe), 2.95–2.87 (m, 1H, H-5), 2.55 (dd, 1H, $J = 5.5$ Hz, $J = 16.2$ Hz, *CHH*), 2.46 (dd, 1H, $J = 6.0$ Hz, $J = 15.4$ Hz, H-6a), 2.40 (dd, 1H, $J = 6.7$ Hz, $J = 15.4$ Hz, H-6b), 2.15 (dd, 1H, $J = 8.9$ Hz, $J = 16.2$ Hz, *CHH*). ¹³C NMR (100 MHz, CDCl₃): δ 205.7 (C-1), 172.3 (C=O CO₂Me), 137.9, 137.6, 137.5 ($3 \times$ C_q Bn), 128.2–127.6 (CH_{arom}), 85.0, 81.6, 79.0 (C-2, C-3, C-4), 74.1, 73.0, 71.8 ($3 \times$ CH₂ Bn), 51.6 (CH₃ OMe), 40.2 (C-6), 33.7 (CH₂CO), 32.0 (C-5). IR (thin film): 1730, 1497, 1454, 1437, 1352, 1205, 1092, 1074, 1051, 1026, 908, 731, 696, 611 cm⁻¹. MS (ESI): $m/z = 489.2$ [M + H]⁺, 511.5 [M + Na]⁺. HRMS (ESI): calcd for [C₃₀H₃₂O₆ + NH₄]⁺ 506.2543. Found 506.2543.

(4*S*,5*R*)-2,4-Bis-benzyloxy-5-methoxycarbonylmethylcyclohex-2-enone (**10**)

Ketone **9** degraded into unsaturated ketone **10** upon storage at room temperature: ¹H NMR (200 MHz, CDCl₃): δ 7.38–7.22 (m, 15H, CH_{arom}), 5.86 (d, 1H, $J_{3,4} = 5.1$ Hz, H-3), 4.89 (d, 1H, $J = 13.2$ Hz, CH Bn), 4.82 (d, 1H, $J = 13.2$ Hz, CH Bn), 4.48 (d, 1H, $J = 11.7$ Hz, CH Bn), 4.41 (d, 1H, $J = 11.7$ Hz, CH Bn), 4.24

(dd, 1H, $J_{4,5} = 2.9$ Hz, $J_{4,3} = 5.1$ Hz, H-4), 3.65 (s, 3H, CH₃ OMe), 2.81-2.29 (m, 5H, H-5, H-6a, H-6b, CHH, CHH). ¹³C NMR (50 MHz, CDCl₃): δ 192.4 (C-1), 172.1 (C=O CO₂Me), 150.3 (C-2), 137.6, 135.3 (2 × C_q Bn), 128.2, 127.9, 127.8, 127.6, 127.3, 126.8, 126.4 (CH_{arom}), 115.1 (C-3), 71.5 (C-4), 70.3, 69.1 (2 × CH₂ Bn), 51.2 (CH₃ OMe), 39.3 (C-6), 35.2 (C-5), 34.3 (CH₂CO₂Me). IR (thin film): 2363, 2343, 1734, 1697, 1624, 1497, 1456, 1261, 1204, 1140, 1067, 1028, 999, 739, 698, 623 cm⁻¹. MS (ESI): $m/z = 403.1$ [M + Na]⁺.

(1S,2R,3S,4R,6S)-1,2,3-Tris-benzyloxy-6-(para-methoxybenzylamino)-4-methoxycarbonylmethylcyclohexane (11)

Enol ether **8** (0.602 g, 1.00 mmol) was cleaved using HF · pyridine, following the procedure described above for the preparation of **9**. After workup, without further purification, intermediate **9** was dissolved in 1,2-DCE (10 mL), followed by addition of Na(OAc)₃BH (0.318 g, 1.50 mmol, 1.5 equiv.). Next, *p*-MeOBnNH₂ (0.261 mL, 2.0 mmol, 2.0 equiv.) and acetic acid (57.7 μL, 1.0 mmol, 1.0 equiv.) were added. The reaction was stirred for 1 h at rt, after which TLC analysis (EtOAc/PE 3:7) indicated the complete disappearance of starting material along with the formation of three lower running spots. The reaction was quenched by the addition of sat. aq. NaHCO₃ and diluted with DCM. The organic phase was collected, dried (MgSO₄), concentrated, and purified by column chromatography (MeOH/DCM 1:99) resulting in protected CSAA **11** (0.311 g, 0.51 mmol) in a yield of 51% over two steps. $[\alpha]_D^{20} +17.0$ (c 0.5, CHCl₃). ¹H NMR (400 MHz, MeOD, T = 333K): δ 7.36–7.23 (m, 15H, CH_{arom} Bn), 7.20–7.15 (m, 2H, CH_{arom} PMB), 6.84–6.80 (m, 2H, CH_{arom} PMB), 4.68 (s, 2H, CH₂ Bn), 4.66 (d, 1H, $J = 11.9$ Hz, CH Bn), 4.55 (d, 1H, $J = 11.9$ Hz, CH Bn), 4.47 (s, 2H, CH₂ Bn), 3.89–3.86 (m, 1H, H-1), 3.85–3.82 (m, 1H, H-3), 3.78–3.75 (m, 1H, H-2), 3.75 (s, 3H, CH₃ OMe PMB), 3.61 (s, 3H, CH₃ OMe), 3.02–2.96 (m, 1H, H-6), 2.69–2.60 (m, 1H, H-4), 2.53 (dd, 1H, $J = 7.2$ Hz, $J_{CHH,CHH} = 15.4$ Hz, CHH), 2.20 (dd, 1H, $J = 7.4$ Hz, $J_{CHH,CHH} = CHH$), 1.72 (ddd, 1H, $J = 4.1$ Hz, $J = 6.8$ Hz, $J_{5a,5b} = 13.5$ Hz, H-5a), 1.58 (ddd, 1H, $J = 3.8$ Hz, $J = 9.0$ Hz, $J_{5b,5a} = 13.5$ Hz, H-5b). IR (thin film): 2872, 1732, 1611, 1510, 1454, 1246, 1099, 737, 698 cm⁻¹. MS (ESI): $m/z = 610.4$ [M + H]⁺, 1220.0 [2M + H]⁺. HRMS (ESI): calcd for [C₃₈H₄₃NO₆ + H]⁺ 610.3169. Found 610.3213.

(3S,4R,6S)-1,3-Bis-benzyloxy-6-(para-methoxybenzylamino)-4-methoxycarbonylmethylcyclohex-1-ene (12)

Enamine **12** (73.0 mg, 0.15 mmol, 15% over two steps) was formed as a minor product in the procedure described above, going from compound **8** to amine **11**. ¹H NMR (300 MHz, CDCl₃): δ 7.37–7.22 (m, 10H, CH_{arom} Bn),

7.20–7.16 (m, 2H, CH_{arom} PMB), 6.84–6.78 (m, 2H, CH_{arom} PMB), 5.09 (d, 1H, $J_{2,3} = 5.4$ Hz, H-2), 4.75 (s, 2H, CH₂ Bn), 4.61 (d, 1H, $J = 11.8$ Hz, CH Bn), 4.40 (d, 1H, $J = 11.8$ Hz, CH Bn), 3.97 (dd, 1H, $J_{3,4} = 3.3$ Hz, $J_{3,2} = 5.4$ Hz, H-3), 3.77–3.67 (m, 2H, CH₂ PMB), 3.76 (s, 3H, CH₃ OMe PMB), 3.64 (s, 3H, CH₃ OMe), 3.47 (dd, 1H, $J = 6.4$ Hz, $J = 10.1$ Hz, H-6), 2.65 (dd, 1H, $J = 7.4$ Hz, $J_{CHH,CHH} = 16.0$ Hz, CHH), 2.49 (dd, 1H, $J = 7.0$ Hz, $J_{CHH,CHH} = 16.0$ Hz, CHH), 2.24–2.15 (m, 1H, H-4), 2.00–1.88 (m, 1H, H-5a), 1.86–1.79 (m, 1H, H-5b). ¹³C NMR (50 MHz, CDCl₃): δ 173.5 (C=O), 158.8 (C_q OMe PMB), 158.4 (C-1), 139.1, 136.6 (2 \times C_q Bn), 132.3 (C_q PMB), 129.3 (CH_{arom} PMB), 128.4, 128.1, 127.9, 127.5, 127.2 (CH_{arom} Bn), 113.6 (CH_{arom} PMB), 96.6 (C-3), 72.0 (C-4), 69.8, 69.1 (2 \times CH₂ Bn), 55.1 (CH₃ OMe PMB), 54.9 (C-6), 51.3 (CH₃ OMe), 49.3 (CH₂ PMB), 36.4 (CH₂CO₂), 34.9 (C-4), 29.5 (C-5). MS (ESI): $m/z = 502.3$ [M + H]⁺, 1003.6 [2M + H]⁺.

(1S,2R,3S,4R,6S)-6-Amino-1,2,3-tris-benzyloxy-4-methoxycarbonylmethylcyclohexane (13)

To a solution of compound **11** (0.476 g, 0.781 mmol) in a mixture of acetonitrile (6 mL) and water (3 mL) was added CAN (1.07 g, 1.95 mmol, 2.5 equiv.). This orange two-phase system was vigorously stirred for 24 h. After addition of sat. aq. NaHCO₃ followed by dilution with EtOAc, the aqueous phase was separated and washed twice with EtOAc. All organic layers were combined, dried (MgSO₄), and concentrated. Purification of the residue by silica gel chromatography (MeOH/DCM 1:19) gave title compound **13** (0.214 g, 0.437 mmol, 56%). ¹H NMR (400 MHz, MeOD): δ 7.39–7.22 (m, 15H, CH_{arom}), 4.67 (d, 1H, $J = 12.3$ Hz, CH Bn), 4.62 (d, 1H, $J = 12.3$ Hz, CH Bn), 4.59 (s, 2H, CH₂ Bn), 4.54 (d, 1H, $J = 12.1$ Hz, CH Bn), 4.48 (d, 1H, $J = 12.1$ Hz, CH Bn), 3.88 (ddd, 1H, $J = 1.2$ Hz, $J = 3.1$ Hz, $J_{2,1} = 4.3$ Hz, H-2), 3.78 (dd, 1H, $J_{1,2} = 3.1$ Hz, $J = 4.4$ Hz, H-1), 3.71 (m, 1H, H-3), 3.65–3.55 (m, 1H, H-6), 3.63 (s, 3H, CH₃ OMe), 2.52 (m, 1H, H-4), 2.45 (dd, $J_{CHH,4} = 7.7$ Hz, $J_{CHH,CHH} = 15.8$ Hz, CHH), 2.27 (dd, 1H, $J_{CHH,4} = 6.5$ Hz, $J_{CHH,CHH} = 15.8$ Hz, CHH), 1.80 (m, 2H, H-5a, H-5b). MS (ESI): $m/z = 490.3$ [M + H]⁺, 979.7 [2M + H]⁺.

(1S,2R,3S,4R,6S)-6-Amino-1,2,3-tris-benzyloxy-4-carboxymethylcyclohexane (14)

To a solution of ester **13** (95 mg, 0.194 mmol) in 1,4-dioxane (2.0 mL), was added an aq. solution of LiOH (0.5 mL, 1.0 M). After 3 h, TLC analysis (MeOH/DCM 15:85) showed complete conversion of starting material into a lower running spot. The mixture was neutralized with 1.0 M aq. HCl to pH 7 and extracted thoroughly with EtOAc (three times). The combined organic phases were dried (MgSO₄) and concentrated to give amino acid **14** (92 mg,

0.194 mmol) in quantitative yield. ^1H NMR (400 MHz, MeOD): δ 7.33–7.26 (m, 15H, CH_{arom}), 4.63 (d, 1H, $J = 12.0$ Hz, CH Bn), 4.57 (d, 1H, $J = 12.0$ Hz, CH Bn), 4.53 (d, 1H, $J = 11.9$ Hz, CH Bn), 4.43 (d, 1H, $J = 11.9$ Hz, CH Bn), 4.40 (d, 1H, $J = 11.8$ Hz, CH Bn), 4.27 (d, 1H, $J = 11.8$ Hz, CH Bn), 3.85–3.82 (ddd, 1H, $J = 1.3$ Hz, $J = 2.9$ Hz, $J_{2,1} = 4.3$ Hz, H-2), 3.76 (dd, 1H, $J = 3.1$ Hz, $J_{1,2} = 4.3$ Hz, H-1), 3.76 (m, 1H, H-3), 3.70 (dd, 1H, $J = 3.6$ Hz, $J = 7.3$ Hz, H-6), 2.51 (m, 1H, H-4), 2.42 (dd, 1H, $J_{\text{CHH},4} = 7.2$ Hz, $J_{\text{CHH},\text{CHH}} = 16.0$ Hz, CHH), 2.29 (1H, dd, $J_{\text{CHH},4} = 6.6$ Hz, $J_{\text{CHH},\text{CHH}} = 16.0$ Hz, CHH), 1.99–1.92 (dddd, 1H, $J = 1.2$ Hz, $J = 3.1$ Hz, $J = 4.1$ Hz, $J_{5a,5b} = 14.8$ Hz, H-5a), 1.86–1.77 (dd, 1H, $J = 3.8$ Hz, $J_{5b,5a} = 14.8$ Hz, H-5b). MS (ESI): $m/z = 476.2$ $[\text{M} + \text{H}]^+$.

(1*S*,2*R*,3*S*,4*R*,6*S*)-*N*-(9-Fluorenylmethoxycarbonyl)-6-amino-1,2,3-tris-benzyloxy-4-carboxymethyl-cyclohexane (**15**)

To a suspension of amino acid **14** (0.194 mmol) in dioxane (0.5 mL) and sat. aq. NaHCO_3 (2.0 mL) was added Fmoc-OSu (85 mg, 0.252 mmol, 1.3 equiv.). After stirring for 17 h, TLC analysis (MeOH/DCM 1:19) revealed complete consumption of starting material into a higher running spot. Water and dioxane were added to the suspension and the resulting solution was acidified with 1.0 M aq. HCl to pH 5. The mixture was diluted with EtOAc, the organic layer was separated, and the aqueous layer was extracted twice with EtOAc. All organic layers were combined, dried (MgSO_4), filtered, and concentrated. After purification by silica gel column chromatography (EtOAc/PE 1:1 + 1.0% HOAc), carbamate **15** was obtained (0.124 g, 0.178 mmol, 92%). $[\alpha]_{\text{D}}^{20} + 25.5$ (c 1.0, CHCl_3). ^1H NMR (600 MHz, C_6D_6): δ 7.56–7.54 (m, 4H, CH_{arom} Fmoc), 7.37–7.30 (m, 4H, CH_{arom} Fmoc), 7.22–7.06 (m, 15H, CH_{arom} Bn), 6.79 (bs, 1H, NH), 4.64 (d, 1H, $J = 11.8$ Hz, CH Bn), 4.60 (d, 1H, $J = 11.8$ Hz, CH Bn), 4.58 (m, 1H, H-6), 4.54 (d, 1H, $J = 11.8$ Hz, CH Bn), 4.50 (dd, 1H, $J = 10.6$ Hz, $J = 7.3$ Hz, CHH, CH_2Fmoc), 4.27 (dd, 1H, $J = 10.6$ Hz, $J = 7.3$ Hz, CHH CH_2Fmoc), 4.22 (m, 1H, CH Bn), 4.16 (m, 3H, CH_2 Bn, CH Fmoc), 3.84 (m, 1H, H-2), 3.74 (m, 1H, H-3), 3.71 (m, 1H, H-1), 2.69 (m, 1H, H-4), 2.40 (m, 1H, CHH $\text{CH}_2\text{CO}_2\text{H}$), 2.11 (m, 1H, CHH $\text{CH}_2\text{CO}_2\text{H}$), 1.92 (m, 1H, H-5a), 1.60 (m, 1H, H-5b). ^{13}C -NMR (100 MHz, CDCl_3): δ 177.6 (C=O CO_2H), 156.5 (C=O Fmoc), 144.1, 141.2 ($2 \times \text{C}_q$ Fmoc), 138.3, 137.9, 137.8 ($3 \times \text{C}_q$ Bn), 129.0, 128.5, 128.4, 128.4, 127.9, 127.8, 127.6, 127.5, 127.0 (CH_{arom} Bn), 125.3, 119.8 (CH_{arom} Fmoc), 77.3 77.0, 76.7 (C-1, C-2, C-3), 73.8, 72.6, 70.4 ($3 \times \text{CH}_2$ Bn), 66.8 (CH_2 Fmoc), 47.8 (C-6), 47.2 (CH Fmoc), 30.7 (CH_2CO_2), 29.7 (C-4), 28.2 (C-5). IR (thin film): 3032, 2924, 2870, 2363, 2341, 1705, 1514, 1452, 1248, 1055, 739, 698 cm^{-1} . MS (ESI): $m/z = 698.5$ $[\text{M} + \text{H}]^+$, 1395.6 $[2\text{M} + \text{H}]^+$. HRMS (ESI): calcd for $[\text{C}_{44}\text{H}_{43}\text{NO}_7 + \text{NH}_4]^+$ 715.3383. Found 715.3370.

H-Phe-Leu-Wang resin (17)

Loading of resin: Commercially available Wang resin **16** (0.96 mmol/g, 1.79 g) was allowed to swell in DCM (40 mL). A solution was prepared of DIC (1.07 mL, 0.87 g, 6.88 mmol, 4.0 equiv.), Fmoc-Leu-OH (2.43 g, 6.88 mmol, 4.0 equiv.), and DMAP (cat.) in DCM. The mixture was left for 16 h with occasional shaking. The resin was filtered, subsequently washed with DMF and DCM, and dried (air). The loading was determined by treatment of the dried resin (2.3 mg) with a solution of 20% piperidine/DMF (1.0 mL). After stirring for 10 min followed by dilution to 10.00 mL with EtOH, the absorption of the solution was measured at 300 nm. The loading was calculated to be 0.49 mmol/g, using the formula: Loading (mmol/g) = $[A_{300}] \cdot 10 / [7.8 \cdot m]$.

Peptide coupling: Fmoc-Leu-Wang-resin (1.00 g, 0.49 mmol) was treated with 10 mL 20% piperidine/DMF (3 × 10 min) to effect Fmoc cleavage. The resin was filtered, washed (DMF and DCM), and swollen in DMF. The resin was treated with a solution of Fmoc-Phe-OH (0.75 g, 1.94 mmol, 4.0 equiv.), HCTU (0.80 g, 1.94 mmol, 4.0 equiv.), and DiPEA (0.64 mL, 3.88 mmol, 8.0 equiv.) in DMF (5.0 mL). After shaking the mixture for 1 h, the resin was filtered and rinsed with DMF. This procedure was repeated twice to ensure complete coupling indicated by a negative Kaiser test. Any unreacted amines were capped using a solution of 0.5 M Ac₂O and 0.125 M DiPEA in DMF (50 mL, 5 min). After filtration and washing with DMF and DCM, the resin was filtered and dried by an air flow. The Fmoc was removed with 20% piperidine/DMF solution as described above.

Fmoc-CSAA-(OBn)₃-Phe-Leu-Wang resin (18)


Resin **17** (70.0 mg, 34.3 μmol) was swollen in DMF. CSAA **15** (47.9 mg, 68.7 μmol, 2.0 equiv.) in DMF (700 μL) was preactivated for 30 sec with HATU (12.0 mg, 32.3 μmol, 0.95 equiv.) and DiPEA (15.0 μL, 84.9 μmol, 2.5 equiv.) and the mixture was subsequently added to the resin and shaken for 10 min. After filtration of the resin, followed by rinsing with DMF, this coupling procedure was repeated once more. After a negative Kaiser test revealed complete consumption of free amines, the resin was washed with DMF and DCM and dried (air flow).

Boc-Tyr(*t*-Bu)-CSAA-(OBn)₃-Phe-Leu-Wang resin (19)

Resin **18** was swollen in DMF followed by Fmoc cleavage using a 20% piperidine/DMF (3 × 10 min), washed with DMF and DCM, filtered, and dried (air). Boc-Tyr(*t*-OBu)-OH (50.6 mg, 0.15 mmol, 4.4 equiv.) was coupled using HCTU (62.1 mg, 0.15 mmol, 4.4 equiv.) and DiPEA (49.6 μL, 0.300 mmol, 8.8 equiv.) in DMF and shaken for 2 h. A negative Kaiser test indicated a complete coupling of the free amines. The resin was filtered, washed with DMF and DCM, and air dried.

H-Tyr-CSAA-Phe-Leu-OH (21)

Cleavage from the resin along with the removal of the *t*-Bu and Boc group was effected transferring immobilized peptide **19** into a glass tube followed by the addition of a mixture of TFA/TIS/water (95:2.5:2.5, 1.0 mL). After shaking for 15 min, the mixture was filtered, washed with DMF and DCM, and dried. Purification by silica gel chromatography (MeOH/DCM 1:9) gave compound **20** (29.4 mg, 32.7 μ mol, 95%). LC/MS (50% to 90% acetonitrile/water), R_t 10.02 min. MS (ESI): $m/z = 899.9$ $[M + H]^+$, 1799.4 $[2M + H]^+$. Compound **20** (16.2 mg, 18.0 μ mol) was dissolved in *t*-BuOH (1.0 mL) and water (1.0 mL), and the resulting solution was degassed. A catalytic amount of Pd/C was added and after degassing the solution was stirred under a hydrogen atmosphere for a second time. After 15 h, TLC analysis (MeOH/DCM 15:85) indicated complete conversion of starting material into a lower running spot. The reaction mixture was filtered over Celite and the filtrate was concentrated to give Leu-enkephalin analog **21** in quantitative yield (11.3 mg, 18.0 μ mol). After HPLC purification (18% to 30% acetonitrile/water), an analytical sample was obtained. LC/MS (10–40% acetonitrile/water), R_t 14.02 min. MS (ESI): $m/z = 629.5$ $[M + H]^+$, 651.4 $[M + Na]^+$, 1257.8 $[2M + H]^+$. ^1H NMR (600 MHz, DMSO d_6 , T = 313K): δ 9.25 (s, 1H), 8.09 (d, 1H, $J = 7.2$ Hz), 7.99 (bs, 1H), 7.84 (d, 1H, $J = 7.2$ Hz), 7.32–6.91 (m, 9H), 6.71–6.68 (m, 2H), 4.62 (m, 1H), 4.48 (m, 1H), 4.20 (m, 1H), 4.04–3.93 (m, 2H), 3.69 (m, 1H), 3.59 (m, 1H), 3.35–3.21 (m, 2H), 3.08–3.00 (m, 2H), 2.81 (m, 1H), 2.78 (m, 1H), 2.64 (m, 1H), 2.31 (m, 1H), 2.23 (m, 1H), 1.95 (m, 1H), 1.77–1.74 (m, 2H), 1.75 (m, 1H), 1.71–1.66 (m, 2H), 0.89 (m, 6H). IR (thin film): 3275, 2963, 2361, 2341, 1678, 1015 cm^{-1} . HRMS (ESI): calcd for $[\text{C}_{32}\text{H}_{44}\text{N}_4\text{O}_9 + \text{H}]^+$ 629.3181. Found 629.3178. The following sequence ions were detected after recording a MS/MS spectrum:



ACKNOWLEDGEMENTS

We thank the Dutch Science Foundation (NWO-CW) for financial support, Kees Erkelens and Fons Lefeber for their assistance with NMR measurements, and Hans van den Elst for recording mass spectra.

REFERENCES

- [1] For reviews see: Gruner, S.A.W.; Locardi, E.; Lohof, E.; Kessler, H. Carbohydrate-based mimetics in drug design: sugar amino acids and carbohydrate scaffolds. *Chem. Rev.* **2002**, *102*, 491–514; (b) Schweizer, F. Glycosamino acids: building blocks for combinatorial synthesis-implications for drug discovery. *Angew. Chem. Int. Ed.* **2002**, *41*, 230–253; (c) Chakraborty, T.K.; Ghosh, S.; Jayaprakash, S. Sugar amino acids and their uses in designing bioactive molecules. *Curr. Med. Chem.* **2002**, *9*, 421–435; (d) Chakraborty, T.K.; Jayaprakash, S.; Ghosh, S. Sugar amino acids based scaffolds-novel peptidomimetics and their potential in combinatorial synthesis. *Combinatorial Chem. High Throughput Screening* **2002**, *5*, 373–387; (e) Gervay-Hague, J.; Weathers, T.M., Jr. Pyranosyl sugar amino acid conjugates: their biological origins, synthetic preparations, and structural characterization. *J. Carbohydr. Chem.* **2002**, *21*, 867–910; (f) Chakraborty, T.K.; Srinivasu, P.; Tapadar, S.; Mohan, B.K. Sugar amino acids and related molecules: some recent developments. *J. Chem. Sci.* **2004**, *116*, 187–207; (g) Jensen, K.J.; Brask, J. Carbohydrates in peptide and protein design. *Biopol.* **2005**, *80*, 747–761.
- [2] Fuchs, E.-F.; Lehmann, J. Polysaccharide analogues, 1. Syntheses of 7-amino-2,6-anhydro-7-deoxy-D-glycero-L-manno-heptonic acid and 7-amino-2,6-anhydro-7-deoxy-D-glycero-D-gulo-heptonic acid. *Chem. Ber.* **1975**, *108*, 2254–2260.
- [3] (a) Graf von Roedern, E.; Kessler, H. A sugar amino acid as a novel peptidomimetic. *Angew. Chem. Int. Ed.* **1994**, *33*, 687–689; (b) Graf von Roedern, E.; Lohof, E.; Hessler, G.; Hoffmann, M.; Kessler, H. Synthesis and conformational analysis of linear and cyclic peptides containing sugar amino acids. *J. Am. Chem. Soc.* **1996**, *118*, 10156–10167.
- [4] (a) Fuchs, E.-F.; Lehmann, J. The synthesis of 5-amino-2,6-anhydro-5-deoxy-D-glycero-D-gulo-heptonic acid and its polycondensation to oligomers. *Carbohydr. Res.* **1976**, *49*, 267–273; (b) Timmers, C.M.; Turner, J.J.; Ward, C.M.; van der Marel, G.A.; Kouwijzer, M.L.; Grootenhuis, P.D.; van Boom, J.H. Synthesis and biological evaluation of backbone-modified phtyoalexin elicitor. *Chem. Eur. J.* **1997**, *3*, 920–929.
- [5] (a) van Well, R.M.; Overkleeft, H.S.; Overhand, M.; Carstensen, E.V.; van der Marel, G.A.; van Boom, J.H. Parallel synthesis of cyclic sugar amino acid/amino acid hybrid molecules. *Tetrahedron Lett.* **2000**, *41*, 9331–9335; (b) van Well, R.M.; Overkleeft, H.S.; van der Marel, G.A.; Bruss, D.; Thibault, G.; de Groot, P.G.; van Boom, J.H.; Overhand, M. Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 331–334; (c) van Well, R.M.; Marinelli, L.; Altona, C.; Erkelens, K.; Siegal, G.; van Raaij, M.; Llamas-Saiz, A.L.; Kessler, H.; Novellino, E.; Lavecchia, A.; van Boom, J.H.; Overhand, M. Conformational analysis of furanoid ϵ -sugar amino acid containing cyclic peptides by NMR spectroscopy, molecular dynamics simulation, and X-ray crystallography: evidence for a novel turn structure. *J. Am. Chem. Soc.* **2003**, *125*, 10822–10829; (d) Grotenbreg, G.M.; Timmer, M.S.M.; Llamas-Saiz, A.L.; Verdoes, M.; van der Marel, G.A.; van Raaij, M.J.; Overkleeft, H.S.; Overhand, M. An unusual reverse turn structure adopted by a furanoid sugar amino acid incorporated in gramicidin S. *J. Am. Chem. Soc.* **2004**, *126*, 3444–3446.

- [6] (a) Lohof, E.; Planker, E.; Mang, C.; Burkhart, F.; Dechantsreiter, M.A.; Haubner, R.; Wester, H.J.; Schwaiger, M.; Hölzemann, G.; Goodman, S.L.; Kessler, H. Carbohydrate derivatives for use in drug design: cyclic α -selective RGD peptides. *Angew. Chem. Int. Ed.* **2000**, *39*, 2761–2764; (b) Locardi, E.; Stöckle, M.; Gruner, S.; Kessler, H. Cyclic homooligomers from sugar amino acids: synthesis, conformational analysis, and significance. *J. Am. Chem. Soc.* **2001**, *123*, 8189–8196; (c) Stöckle, M.; Voll, G.; Gunther, R.; Lohof, E.; Locardi, E.; Gruner, S.; Kessler, H. Synthesis and NMR studies of cyclopeptides containing a sugar amino acid. *Org. Lett.* **2002**, *4*, 2501–2504; (d) Gruner, S.A.W.; Truffault, V.; Voll, G.; Locardi, E.; Stöckle, M.; Kessler, H. Design, synthesis, and NMR structure of linear and cyclic oligomers containing novel furanoid sugar amino acids. *Chem. Eur. J.* **2002**, *8*, 4365–4376; (e) Billing, J.F.; Nilsson, U.J. Synthesis of a C_3 -symmetric macrocycle with alternating sugar amino acid and tyrosine residues. *Tetrahedron Lett.* **2005**, *46*, 991–993; (f) Menand, M.; Blais, J.C.; Hamon, L.; Valery, J.M.; Xie, J. Synthesis of orthogonally protected cyclic homooligomers from sugar amino acids. *J. Org. Chem.* **2005**, *70*, 4423–4430.
- [7] (a) van Well, R.M.; Marinelli, L.; Erkelens, K.; van der Marel, G.A.; Lavecchia, A.; Overkleeft, H.S.; van Boom, J.H.; Kessler, H.; Overhand, M. Synthesis and structural analysis of cyclic oligomers consisting of furanoid and pyranoid ϵ -sugar amino acids. *Eur. J. Org. Chem.* **2003**, *12*, 2303–2313; (b) Mayes, B.A.; Stetz, R.J.E.; Ansell, C.W.G.; Fleet, G.W.J. Cyclo[(6-amino-6-deoxy-D-galactonic acid)₄]: a new class of carbopeptoid-cyclodextrin. *Tetrahedron Lett.* **2004**, *45*, 153–156.
- [8] Smith, A.B., III; Sasho, S.; Barwis, B.A.; Sprengeler, P.; Barbosa, J.; Hirschmann, R.; Cooperman, B.S. Design and synthesis of a tetrahydropyran-based inhibitor of mammalian ribonucleotide reductase. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 3133–3136.
- [9] (a) Poitout, L.; Le Merrer, Y.; Depezay, J. Synthesis of sugar-like aminocarboxylic acids from D-mannitol. *Tetrahedron Lett.* **1995**, *36*, 6887–6890; (b) McDevitt, J.P.; Lansbury, P.T., Jr. Glycosamino acids: new building blocks for combinatorial synthesis. *J. Am. Chem. Soc.* **1996**, *118*, 3818–3828; (c) Hungerford, N.L.; Claridge, T.D.W.; Watterson, M.P.; Aplin, R.T.; Moreno, A.; Fleet, G.W.J. Tetrahydrofuran amino acids: secondary structure in tetrameric and octameric carbopeptoids derived from a D-allo 5-(aminomethyl)-tetrahydrofuran-2-carboxylic acid. *J. Chem. Soc., Perkin Trans. 1* **2000**, 3666–3679; (d) Raunkjær, M.; El Oualid, F.; van der Marel, G.A.; Overkleeft, H.S.; Overhand, M. Alkylated sugar amino acids: a new entry toward highly functionalized dipeptide isosters. *Org. Lett.* **2004**, *6*, 3167–3170; (e) Edwards, A.A.; Sanjayan, G.J.; Hachisu, S.; Soengas, R.; Stewart, A.; Tranter, G.E.; Fleet, G.W.J. Synthesis of 4-aminomethyl-tetrahydrofuran-2-carboxylates with 2,4-cis and 2,4-trans relationships. *Tetrahedron* **2006**, *62*, 4110–4119.
- [10] (a) Peri, F.; Cipolla, L.; La Ferla, B.; Nicotra, F. Synthesis of bicyclic sugar azido acids and their incorporation in cyclic peptides. *Chem. Commun.* **2000**, *23*, 2303–2304; (b) van Well, R.M.; Meijer, M.E.A.; Overkleeft, H.S.; van Boom, J.H.; van der Marel, G.A.; Overhand, M. Synthesis of bridged sugar amino acids: a new entry into conformationally locked δ - and ϵ -amino acids. *Tetrahedron* **2003**, *59*, 2423–2434; (c) Grotenbreg, G.M.; Tuin, A.W.; Witte, M.D.; Leeuwenburgh, M.A.; van Boom, J.H.; van der Marel, G.A.; Overkleeft, H.S.; Overhand, M. An expeditious route towards pyranopyran sugar amino acids. *Synlett* **2004**, *5*, 904–906.
- [11] (a) Chakraborty, T.K.; Ghosh, S.; Jayaprakash, S.; Sharma, J.A.R.P.; Ravikanth, V.; Diwan, P.V.; Nagaraj, R.; Kunwar, A.C. Synthesis and conformational studies of peptidomimetics containing furanoid sugar amino acids and a sugar diacid. *J. Org. Chem.* **2000**, *65*, 6441–6457; (b) Gregar, T.Q.; Gervay-Hague, J. Synthesis

- of oligomers derived from amide-linked neuraminic acid analogues. *J. Org. Chem.* **2004**, *69*, 1001–1009; (c) Mayes, B.A.; Stetz, R.J.E.; Watterson, M.P.; Edwards, A.A.; Ansell, C.W.G.; Tranter, G.E.; Fleet, G.W.J. Towards hydroxylated nylon 6: linear and cyclic oligomers from a protected 6-amino-6-deoxy-D-galactonate—a novel class of carbopeptoid-cyclodextrin (CPCD). *Tetrahedron-Asymm.* **2004**, *15*, 627–638.
- [12] (a) Fairbanks, A.J.; Hui, A.; Skead, B.M.; Lilley, P.M. de Q.; Lamont, R.B.; Storer, R.; Saunders, J.; Watkin, D.J.; Fleet, G.W.J. Polyhydroxylated cyclohexane and cyclopentane α -amino acids from cyclisations of an azidolactone. *Tetrahedron Lett.* **1994**, *47*, 8891–8894; (b) Rassu, G.; Auzzas, L.; Pinna, L.; Zambrano, V.; Zanardi, F.; Battistini, L.; Marzocchi, L.; Acquotti, D.; Casiraghi, G. Variable strategy toward carbasugars and relatives. 4. Viable access to (4a-carbapentofuranosyl)amines, (5a-carbahexopyranosyl)amines, and amino acids thereof. *J. Org. Chem.* **2002**, *67*, 5338–5342; (c) Carballido, M.; Castedo, L.; González-Bello, C. Synthesis of amino carba sugars and conformationally restricted polyhydroxy γ -amino acids from (–)-quinic acid. *Eur. J. Org. Chem.* **2004**, 3663–3668; (d) Rassu, G.; Auzzas, L.; Zambrano, V.; Burreddu, P.; Pinna, L.; Battistini, L.; Zanardi, F.; Casiraghi, G. Variable strategy toward carbasugars and relatives. 6. Diastereoselective synthesis of 2-deoxy-2-amino-5a-carba- β -L-mannopyranuronic acid and 2-deoxy-2-amino-5a-carba- β -L-mannopyranose. *J. Org. Chem.* **2004**, *69*, 1625–1628.
- [13] (a) Ferrier, R.J.; Middleton, S. The conversion of carbohydrate derivatives into functionalized cyclohexanes and cyclopentanes. *Chem. Rev.* **1993**, *93*, 2779–2831; (b) Das, K.S.; Mallet, D.-J.; Sinaÿ, P. Novel carbocyclic ring closure of hex-5-enopyranosides. *Angew. Chem. Int. Ed.* **1997**, *36*, 493–496; (c) Martínez-Grau, A.; Marco-Contellas, J. Carbocycles from carbohydrates via free radical cyclizations: new synthetic approaches to glycomimetics. *Chem. Soc. Rev.* **1998**, *27*, 155–162; (d) Dalko, P.I.; Sinaÿ, P. Recent advances in the conversion of carbohydrate furanoides and pyranoides into carbocycles. *Angew. Chem. Int. Ed.* **1999**, *38*, 773–777; (e) Jørgensen, M.; Hadwiger, P.; Madsen, R.; Stütz, A.E.; Wrodnigg, T.M. Olefine metathesis in carbohydrate chemistry. *Curr. Org. Chem.* **2000**, *4*, 565–588; (f) Rassu, G.; Auzzas, L.; Pinna, L.; Battistini, L.; Zanardi, F.; Marzocchi, L.; Acquotti, D.; Casiraghi, G. Variable strategy toward carbasugars and relatives. 1. Stereocontrolled synthesis of pseudo- β -D-gulopyranose, pseudo- β -D-xylofuranose, (pseudo- β -D-gulopyranosyl)amino, and (pseudo- β -D-xylofuranosyl) amine. *J. Org. Chem.* **2000**, *65*, 6307–6318; (g) Callam, C.S.; Lowary, T.L. Synthesis and conformational investigation of methyl 4a-carba-D-arabinofuranosides. *J. Org. Chem.* **2001**, *66*, 8961–8972; (h) Ferrier, R.J. Direct conversion of 5,6-unsaturated hexopyranosyl compounds to functionalized cyclohexanones. *Top. Curr. Chem.* **2001**, *215*, 277–291; (i) Gómez, A.M.; Moreno, E.; Valverde, S.; López, J.C. A general stereodivergent strategy for the preparation of carbasugars. Syntheses of 5a-carba- α -D-glucose, α -D-galactose, and β -L-gulose pentaacetates from D-mannose. *Tetrahedron Lett.* **2002**, *43*, 5559–5562; (j) Ovaia, H.; Lastdrager, B.; Codeé, J.D.C.; van der Marel, G.A.; Overkleeft, H.S.; van Boom, J.H. A flexible synthesis of cyclopentitol derivatives based on ring-closing metathesis of carbohydrate-derived 1,6-dienes. *J. Chem. Soc., Perkin Trans. 1* **2002**, 2370–2377.
- [14] Ferrier, R.J. Unsaturated carbohydrates. Part 21. A carbocyclic ring closure of a hex-5-enopyranoside derivative. *J. Chem. Soc., Perkin Trans. 1* **1979**, 1455–1458.
- [15] (a) Jaramillo, C.; Chiara, J.L.; Martin-Lomas, M. An effective strategy for the synthesis of 6-O-(2-amino-2-deoxy- α -D-glucopyranosyl)-D-chiro- and -D-myoinositol 1-phosphate related to putative insulin mimetics. *J. Org. Chem.* **1994**, *59*, 3135–3141; (b) Hladezuk, I.; Olesker, A.; Tchertanov, L.; Cléophax, J. Preparation

of novel polysubstituted chiral cyclohexanone derivatives containing a quaternary carbon by Ferrier reaction. *Carbohydr. Res.* **2001**, *330*, 257–265.

- [16] Kita, Y.; Segawa, J.; Haruta, J.-I.; Yasuda, H.; Tamura, Y. Keten silyl acetal chemistry; simple synthesis of methyl Jasmonate and related compounds by utilizing keten methyl dimethyl-*t*-butylsilyl acetal. *J. Chem. Soc., Perkin Trans. 1* **1982**, 1099–1104. 1-(*tert*-Butyldimethylsilyloxy)-1-ethoxyethene was prepared by reaction of ethyl acetate, freshly made LDA, and TBS-Cl according to a literature procedure.
- [17] Grieco, G.A.; Cooke, R.J.; Henry, K.J.; Van der Roest, J.M. Lithium perchlorate catalyzed conjugate addition of O-silylated ketene acetals to hindered α,β -unsaturated carbonyl compounds at atmospheric pressure. *Tetrahedron Lett.* **1991**, *32*, 4665–4668.